American Trust Decreases Stock Position in Stryker Corporation $SYK

American Trust cut its holdings in Stryker Corporation (NYSE:SYK) by 24.8% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 9,644 shares of the medical technology company’s stock after selling 3,176 shares during the period. American Trust’s holdings in Stryker were worth $3,590,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the business. Brighton Jones LLC increased its position in Stryker by 15.4% during the fourth quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock worth $1,643,000 after buying an additional 609 shares in the last quarter. Gotham Asset Management LLC increased its position in Stryker by 139.8% during the fourth quarter. Gotham Asset Management LLC now owns 4,251 shares of the medical technology company’s stock worth $1,531,000 after buying an additional 2,478 shares in the last quarter. Investor s Fiduciary Advisor Network LLC purchased a new position in Stryker during the fourth quarter worth $483,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Stryker by 1.3% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 60,503 shares of the medical technology company’s stock worth $21,784,000 after buying an additional 754 shares in the last quarter. Finally, Meridiem Capital Partners LP purchased a new position in Stryker during the fourth quarter worth $5,900,000. 77.09% of the stock is owned by hedge funds and other institutional investors.

Stryker Stock Up 0.2%

Shares of NYSE SYK opened at $393.12 on Tuesday. Stryker Corporation has a 52-week low of $329.16 and a 52-week high of $406.19. The firm has a fifty day moving average of $389.47 and a 200-day moving average of $379.58. The stock has a market capitalization of $150.29 billion, a PE ratio of 52.07, a P/E/G ratio of 2.85 and a beta of 0.93. The company has a quick ratio of 1.06, a current ratio of 1.78 and a debt-to-equity ratio of 0.70.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, July 31st. The medical technology company reported $3.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.07 by $0.06. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The company had revenue of $6.02 billion during the quarter, compared to analysts’ expectations of $5.92 billion. During the same period in the previous year, the company earned $2.81 EPS. The business’s quarterly revenue was up 11.1% compared to the same quarter last year. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. On average, analysts anticipate that Stryker Corporation will post 13.47 EPS for the current year.

Stryker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be paid a dividend of $0.84 per share. The ex-dividend date of this dividend is Tuesday, September 30th. This represents a $3.36 annualized dividend and a dividend yield of 0.9%. Stryker’s payout ratio is currently 44.50%.

Insider Buying and Selling at Stryker

In other news, insider Viju Menon sold 500 shares of the business’s stock in a transaction on Monday, August 25th. The shares were sold at an average price of $390.61, for a total transaction of $195,305.00. Following the completion of the sale, the insider directly owned 12,511 shares of the company’s stock, valued at $4,886,921.71. The trade was a 3.84% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Ronda E. Stryker sold 200,000 shares of the business’s stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the sale, the director directly owned 3,222,108 shares of the company’s stock, valued at $1,212,962,556.60. This represents a 5.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.20% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on SYK shares. Wells Fargo & Company raised their price target on Stryker from $435.00 to $445.00 and gave the stock an “overweight” rating in a research report on Friday, August 1st. Citigroup reissued a “buy” rating and set a $455.00 price target (up previously from $443.00) on shares of Stryker in a research report on Thursday, May 22nd. Truist Financial set a $415.00 target price on shares of Stryker and gave the stock a “hold” rating in a research note on Monday, August 4th. Needham & Company LLC lifted their target price on shares of Stryker from $442.00 to $448.00 and gave the stock a “buy” rating in a research note on Friday, August 1st. Finally, BTIG Research reaffirmed a “buy” rating on shares of Stryker in a research note on Monday, July 14th. Fifteen investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $430.10.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.